Market Overview:
The global transthyretin market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of transthyretin-related diseases, rising awareness about these diseases, and the launch of novel therapeutics. Based on type, the global transthyretin market is segmented into AG-10, ALN-TTRsc02, CRX-1008, EDE-1307, inotersen sodium (IONIS), and others. IONIS is expected to dominate the market during the forecast period owing to its high efficacy and safety profile. Based on application, familial amyloid neuropathies (FANs) are estimated to account for a major share of the global transthyretin market in 2018. This can be attributed to increasing awareness about FANs and availability of novel therapies for their treatment such as IONIS and EDE 1307. Alzheimer's disease (AD) is another key application area for transthyretin therapeutics due to rising incidence rates globally. Other key applications areas include cardiomyopathy and neuropathy. Geographically, North America dominates the global transthyretin market followed by Europe owingto early adoption of novel therapies in these regions coupled with strong presenceof leading players such as Ionis Pharmaceuticals Inc.
Product Definition:
A serum protein that transports thyroid hormones and retinol (vitamin A) in the blood. It is important for normal fetal development and metabolism.
AG-10:
AG-10 is a form of transthyretin, which is an amino acid that the body cannot produce and must be obtained from external sources. It functions as a blood clotting agent and helps in maintaining the fluid levels in eyes. The main function of AG-10 is to help maintain normal retinal functioning by helping with blood vessel dilation & constriction, thus enabling normal vision.
ALN-TTRsc02:
ALN-TTRsc02 is a genetically engineered form of transthyretin, which is produced by the modification of human tTR-type 1 cell line. ALN-TTRsc02 has an amino acid sequence similar to that of native transthyretin and can bind all four types of thyroid hormones with high affinity.
Application Insights:
Familial amyloid neuropathy (FAN) was the leading application segment in 2017 and accounted for a revenue share of over 40%. The increasing prevalence of FAN is one of the major factors driving this segment. According to data published by Genetics Home Reference, around 1 in 4,000 babies are born with FAN.
The others segment includes transthyretin-related disorders such as cardiomyopathy and nephrological disease. Cardiomyopathy is a common disorder associated with TTR; however, it can be managed through lifestyle modifications along with medication if needed. Thus, this application segment is expected to witness lucrative growth during the forecast period owing to rising awareness about treatment options for cardiomyopathy among patients across the globe.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of players coupled with high R&D expenditure and focus on product innovation is expected to drive the regional market over the forecast period. In addition, increasing prevalence of neurodegenerative diseases, rising geriatric population and availability of reimbursement are some other factors that can be attributed to regional growth.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to untapped opportunities in this region. There has been an increase in awareness regarding transthyretin deficiency among patients as well as physicians due to which there has been an upsurge in demand for AG-10, ALN-TTRsc02 and CRX-1008 products from countries such as China & Japan & South Korea etc., thereby driving growth across this region.
Growth Factors:
- Increasing prevalence of transthyretin-related diseases such as amyloidosis, familial amyloid polyneuropathy, and senile systemic amyloidosis
- Growing demand for novel therapeutics for the treatment of transthyretin-related diseases
- Rising awareness about transthyretin-related diseases among patients and healthcare professionals
- increasing investment in research and development activities for the discovery of new therapies for transthyretin-related diseases
- growing number of clinical trials evaluating novel therapeutics for the treatment of transthyretin-related diseases
Scope Of The Report
Report Attributes
Report Details
Report Title
Transthyretin Market Research Report
By Type
AG-10, ALN-TTRsc02, CRX-1008, EDE-1307, Inotersen Sodium, Others
By Application
Familial Amyloid Neuropathies, Alzheimer's Disease, Cardomyopathy, Neuropathy, Others
By Companies
Alnylam Pharmaceuticals Inc, Arcturus Therapeutics Inc, Ionis Pharmaceuticals Inc, Neurimmune Holding AG, Pfizer Inc, Prothena Corp Plc, Regeneron Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
203
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Transthyretin Market Report Segments:
The global Transthyretin market is segmented on the basis of:
Types
AG-10, ALN-TTRsc02, CRX-1008, EDE-1307, Inotersen Sodium, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Familial Amyloid Neuropathies, Alzheimer's Disease, Cardomyopathy, Neuropathy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alnylam Pharmaceuticals Inc
- Arcturus Therapeutics Inc
- Ionis Pharmaceuticals Inc
- Neurimmune Holding AG
- Pfizer Inc
- Prothena Corp Plc
- Regeneron Pharmaceuticals Inc
- Alnylam Pharmaceuticals Inc
Highlights of The Transthyretin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AG-10
- ALN-TTRsc02
- CRX-1008
- EDE-1307
- Inotersen Sodium
- Others
- By Application:
- Familial Amyloid Neuropathies
- Alzheimer's Disease
- Cardomyopathy
- Neuropathy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Transthyretin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Transthyretin is a protein that helps control the flow of blood. It is found in the blood vessels and in the central nervous system. Transthyretin helps to keep your heart functioning properly and can help to prevent strokes.
Some of the major players in the transthyretin market are Alnylam Pharmaceuticals Inc, Arcturus Therapeutics Inc, Ionis Pharmaceuticals Inc, Neurimmune Holding AG, Pfizer Inc, Prothena Corp Plc, Regeneron Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Transthyretin Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Transthyretin Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Transthyretin Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Transthyretin Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Transthyretin Market Size & Forecast, 2020-2028 4.5.1 Transthyretin Market Size and Y-o-Y Growth 4.5.2 Transthyretin Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 AG-10
5.2.2 ALN-TTRsc02
5.2.3 CRX-1008
5.2.4 EDE-1307
5.2.5 Inotersen Sodium
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Familial Amyloid Neuropathies
6.2.2 Alzheimer's Disease
6.2.3 Cardomyopathy
6.2.4 Neuropathy
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Transthyretin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Transthyretin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 AG-10
9.6.2 ALN-TTRsc02
9.6.3 CRX-1008
9.6.4 EDE-1307
9.6.5 Inotersen Sodium
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Familial Amyloid Neuropathies
9.10.2 Alzheimer's Disease
9.10.3 Cardomyopathy
9.10.4 Neuropathy
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 AG-10
10.6.2 ALN-TTRsc02
10.6.3 CRX-1008
10.6.4 EDE-1307
10.6.5 Inotersen Sodium
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Familial Amyloid Neuropathies
10.10.2 Alzheimer's Disease
10.10.3 Cardomyopathy
10.10.4 Neuropathy
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 AG-10
11.6.2 ALN-TTRsc02
11.6.3 CRX-1008
11.6.4 EDE-1307
11.6.5 Inotersen Sodium
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Familial Amyloid Neuropathies
11.10.2 Alzheimer's Disease
11.10.3 Cardomyopathy
11.10.4 Neuropathy
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 AG-10
12.6.2 ALN-TTRsc02
12.6.3 CRX-1008
12.6.4 EDE-1307
12.6.5 Inotersen Sodium
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Familial Amyloid Neuropathies
12.10.2 Alzheimer's Disease
12.10.3 Cardomyopathy
12.10.4 Neuropathy
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 AG-10
13.6.2 ALN-TTRsc02
13.6.3 CRX-1008
13.6.4 EDE-1307
13.6.5 Inotersen Sodium
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Familial Amyloid Neuropathies
13.10.2 Alzheimer's Disease
13.10.3 Cardomyopathy
13.10.4 Neuropathy
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Transthyretin Market: Competitive Dashboard
14.2 Global Transthyretin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Alnylam Pharmaceuticals Inc
14.3.2 Arcturus Therapeutics Inc
14.3.3 Ionis Pharmaceuticals Inc
14.3.4 Neurimmune Holding AG
14.3.5 Pfizer Inc
14.3.6 Prothena Corp Plc
14.3.7 Regeneron Pharmaceuticals Inc
14.3.8 Alnylam Pharmaceuticals Inc